IMDS Operations B.V.

IMDS Operations B.V. specializes in devices used for percutaneous coronary interventions (PCI), a minimally invasive procedure to treat narrowed or blocked coronary arteries. Their portfolio includes guide catheters (like Guidion and GuidionShort), microcatheters (Micro Rx), aspiration devices (TrapIt), intravascular imaging tools (ShapeIT), drug-coated balloons (NHANCER and NHancer Rx), and guidewires (FlowGuide and ReCross). These products are designed to enhance precision and outcomes in coronary artery treatments.

IMDS Operations B.V. is headquartered in the Netherlands. The company’s location in the Netherlands provides a strategic base for developing and distributing medical devices, particularly those focused on advanced coronary intervention technologies.

IMDS Operations B.V.’s devices are listed in the EUDAMED database, which is the European Union’s transparency system for medical devices. Additionally, their products appear in the FDA’s 510(k) registry, which tracks devices seeking clearance under the U.S. premarket notification process. These listings reflect their compliance with EU and FDA regulatory requirements.

IMDS Operations B.V.’s devices are classified as either Class II or Class III under both EU and FDA frameworks. Class II devices generally pose moderate risks and require special controls beyond general controls, while Class III devices are high-risk and typically require premarket approval. The classification depends on factors like the device’s intended use, potential risks, and the body area it interacts with, ensuring appropriate regulatory oversight.

Class III classification is reserved for devices that support or sustain life, are of substantial importance in preventing impairment of human health, or present a potential unreasonable risk of illness or injury. In IMDS’s portfolio, certain devices—such as drug-coated balloons (NHANCER, NHancer Rx) or intravascular imaging tools (ShapeIT)—may fall into this category due to their critical role in diagnosing or treating life-threatening coronary conditions. The classification ensures rigorous evaluation to confirm their safety and effectiveness before market authorization.